Apremilast for oral ulcers associated with active Behcet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial

Tarih
2021
Yazar
Mccue, S.
Mahr, A.
Takeno, M.
Kim, D. Y.
Saadoun, D.
DİRESKENELİ, RAFİ HANER
Melikoglu, M.
Cheng, S.
Paris, M.
Yazici, Y.
Chen, M.
Hatemi, G.
Üst veri
Tüm öğe kaydını göster
Özet
Objective. This study assessed the efficacy and safety of apremilast for the oral ulcers associated with Behcet's syndrome (BS) up to 64 weeks.
Bağlantı
http://hdl.handle.net/20.500.12627/172224
Koleksiyonlar